(Reuters) – Gene sequencing company Illumina Inc
Grail could fetch more than the $6 billion valuation that it had reached from previous fundraisings, the report https://www.bloomberg.com/news/articles/2020-09-16/illumina-said-to-be-in-talks-to-buy-health-care-startup-grail?sref=vEQJzSks said, adding the companies could announce a deal as soon as this week.
Both Illumina and Grail did not immediately respond to Reuters requests for comment.
Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by Amazon.com Inc’s
Illumina is the single largest shareholder in Grail with a 14.6% stake, according to the company’s filing for a U.S. listing last week.
In January, Illumina ended its $1.2 billion deal to buy smaller rival Pacific Biosciences of California Inc
Shares of Illumina were down 4.8% at $334.9 in morning trading.
(Reporting by Dania Nadeem in Bengaluru; Editing by Arun Koyyur)